Genomics
PrivateLast Round
VC Round
Jan 8, 2024
Est. Valuation
$40.66M
Total Funding Raised
$58.86M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Genomics is a biotechnology company that specializes in genetic inference technology to identify new drug targets for serious diseases, utilizing an analytical platform to enhance DNA sequencing impact and support pharmaceutical firms in de-risking drug development while improving healthcare outcomes.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Precision Medicine, Healthcare Analytics, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genomics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jan 8, 2024 | ||||
| VC Round | Mar 1, 2021 | ||||
| Series B | Dec 10, 2018 | ||||
| Series A | Nov 26, 2014 |
Key People
Founding team and executive leadership
Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Infinity Investment Partners | VC Round |
| IP Group | Series A, Series B |
| Oxford Science Enterprises | Series B, VC Round |
| F-Prime Capital | Series B, VC Round |
| Tanarra | Series B |
| University of Oxford | Series A |
| Woodford Investment Management | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 30, 2026
Partnered with Greywolf to develop ERAP autoimmune disease treatments.
- Apr 30, 2026
Developing first-in-class ERAP autoimmune disease treatments with Greywolf.
Genomics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Genomics's valuation, stock price, and market status.